A gastric retained dosage form of gabapentin

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/195 (2006.01) A61K 9/22 (2006.01) A61P 25/02 (2006.01) A61P 25/06 (2006.01) A61P 25/08 (2006.01) A61P 25/14 (2006.01) A61P 25/18 (2006.01)

Patent

CA 2575555

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. Further, an extended release oral dosage form for releasing gabapentin into the stomach, duodenum ans small intestine of the mammal, comprising a core comprising at least 800 mg of gabapentin, surrounded by a semipermeable membrane is described.

La présente invention a trait à un procédé de traitement pour l'épilepsie et d'autres états pathologiques, comprenant l'administration de la gabapentine en une forme de dosage à rétention gastrique. L'invention a également trait à une forme de dosage orale à libération prolongée pour la libération de la gabapentine dans l'estomac, le duodénum et l'intestin grêle du mammifère, comportant un noyau comprenant au moins 800 mg de gabapentine, enrobé d'une membrane semi-perméable.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

A gastric retained dosage form of gabapentin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with A gastric retained dosage form of gabapentin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A gastric retained dosage form of gabapentin will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1957621

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.